Program
Lomustine
Also written as “Lomustine (CCNU)”, “L19TNF and CCNU” and “nab-sirolimus + lomustine”.
Its studies are mostly in Glioblastoma · Glioma, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 21 open or running | phase 2since Jul 30, 2025 | Feb 24, 2022 | Jan 30, 2029phase 2 · NCT07120984 |
| Aadi Bioscience | 10 open or running | phase 2since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 2since Jul 28, 2009 | Jul 28, 2009 | none ahead |
| Eli Lilly | 10 open or running | phase 2since Apr 19, 2012 | Apr 19, 2012 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since May 21, 2013 | May 21, 2013 | none ahead |
| Karyopharm Therapeutics | 10 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Novartis | 10 open or running | phase 1since Aug 20, 2013 | Aug 20, 2013 | none ahead |
| Pfizer | 10 open or running | phase 3since Sep 12, 2003 | Sep 12, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2003First study: phase 3 study in GlioblastomaNew to PfizerPfizer · NCT00068952 · 118 enrolled · United States, Australia, Austria and more
- Jul 28, 2009Bristol-Myers Squibb's first study: phase 2 study in GlioblastomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00948389 · 28 enrolled · France, Italy, Netherlands and more
- Apr 19, 2012Eli Lilly's first study: phase 2 study in GlioblastomaNew to Eli LillyEli Lilly · NCT01582269 · 158 enrolled · United States, Australia, Belgium and more
- May 21, 2013Hoffmann-La Roche's first study: phase 2 study in GlioblastomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01860638 · 296 enrolled · Austria, Bulgaria, Canada and more
- Aug 20, 2013Novartis's first study: phase 1 study in GlioblastomaNew to NovartisNovartis · NCT01934361 · 35 enrolled · United States, Australia, Belgium and more
- Mar 5, 2018Aadi Bioscience's first study: phase 2 study in High Grade Recurrent Glioma and Newly Diagnosed GlioblastomaNew to Aadi BioscienceAadi Bioscience · NCT03463265 · 62 enrolled · United States
- Jun 1, 2020Karyopharm Therapeutics's first study: phase 2 study in GlioblastomaNew to Karyopharm TherapeuticsKaryopharm Therapeutics · NCT04421378 · 74 enrolled · United States, Canada
- Feb 24, 2022Philogen's first study: phase 1 study in GlioblastomaNew to PhilogenPhilogen · NCT05304663
- Jul 30, 2025Phase 2 study in GliomaPhilogen · NCT07120984 · 52 planned
Ahead
- Jan 30, 2029Primary completion: phase 2 study in GliomaPhilogen · NCT07120984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07120984Glioma | 2 | Not yet recruiting | Philogen | Jan 30, 2029 | 52 |
| NCT05304663Glioblastoma | 1 | Withdrawn | Philogen | Dec 31, 2024 | 0 |
| NCT04421378Glioblastoma · United States, Canada | 2 | Terminated | Karyopharm Therapeutics | Jul 3, 2023 | 74 |
| NCT03463265High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma · United States | 2 | Completed | Aadi Bioscience | Aug 26, 2022 | 62 |
| NCT01934361Glioblastoma · United States, Australia, Belgium and more | 1 | Completed | Novartis | Jul 7, 2016 | 35 |
| NCT01860638Glioblastoma · Austria, Bulgaria, Canada and more | 2 | Completed | Hoffmann-La Roche | Jan 13, 2017 | 296 |
| NCT01582269Glioblastoma · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Jul 26, 2014 | 158 |
| NCT00948389Glioblastoma · France, Italy, Netherlands and more | 2 | Terminated | Bristol-Myers Squibb | May 2011 | 28 |
| NCT00068952Glioblastoma · United States, Australia, Austria and more | 3 | Completed | Pfizer | 118 |
How it is read
Names in the registry
- “Lomustine”, 4 entries
- “Lomustine (CCNU)”, 2 entries
- “L19TNF and CCNU”, 1 entry
- “nab-sirolimus + lomustine”, 1 entry
- “lomustine”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 8 studies
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.